Irritable Bowel Syndrome (IBS)

ნაწლავები · §73

Recurring belly pain that ties to your bathroom habits, in a body where every scan and blood test comes back normal, isn't a mystery — it's irritable bowel syndrome, and it affects somewhere between one in twenty-five and one in ten adults worldwide. The diagnosis is positive, not made by exclusion: the Rome IV criteria are specific enough that a careful symptom history plus a short workup nails it. Most people who follow a structured plan — a three-phase elimination diet, a couple of cheap supplements, sometimes a low-dose medication or a gut-directed behavioural program — get meaningfully better.

Respond · Course Evidence Moderate თავი ნაწლავები

Treated properly, this is one of the bigger felt-quality-of-life shifts you can buy: pain, urgency and bloating ease within weeks, mood and energy follow as the gut quiets down, sleep stops being held hostage to morning dread. The catch is the work — the elimination-and-reintroduction phase is several months of reading every ingredient label and tracking what you eat. Get a dietitian if you can; the protocol falls apart self-directed.

The gut and brain talk to each other constantly — through the vagus nerve, the enteric nervous system (your bowel's own network of roughly 100 million neurons), immune signals, microbial metabolites, and hormones. In IBS that conversation is miscalibrated. Normal amounts of gas and stretch in the bowel register as pain. Stress that wouldn't have moved your gut a decade ago now flares it. This is what gastroenterologists mean when they call IBS a disorder of gut-brain interaction — not "in your head", but in the wiring between the two Drossman 2016.

The Rome IV criteria turn this into something a clinician can diagnose in one visit: belly pain at least one day a week over the last three months, plus two of three — pain that relates to going to the bathroom, a change in how often you go, or a change in what your stool looks like Lacy & Patel 2017. The subtype falls out of which stool form dominates on the Bristol Stool Form Scale, a seven-point picture chart where Type 1 is hard separate lumps and Type 7 is entirely liquid:

IBS-C — mostly constipation. Stools usually hard or lumpy (Bristol 1–2).
IBS-D — mostly diarrhoea. Stools usually loose or watery (Bristol 6–7).
IBS-M — both, alternating. Hard days and loose days each pass the 25% threshold.
IBS-U — unclassified. Symptoms fit IBS, but stool form doesn't pile up enough on either end to subtype.

The subtype matters because the treatment ladder splits at it — psyllium and secretagogues skew toward the constipation end, loperamide and rifaximin toward the diarrhoea end. Most other steps work across all four.

Does any of this actually work

The diagnosis itself is durable: over 90% of adults who meet Rome IV in specialist clinics still meet criteria years later, and organic disease shows up afterwards only rarely Lacy & Patel 2017. You're not waiting on a missed diagnosis — once IBS is on the chart with the workup done, it stays IBS.

The treatments hold up too. Each major step has been tested against placebo or a control diet in randomised trials, and the numbers most readers care about — how many people get meaningfully better — are good for a chronic functional condition:

The low-FODMAP diet — global symptoms improve in roughly half to three-quarters of people who do it properly. Bloating and pain ease within two to four weeks of the elimination phase Halmos 2014.
Soluble fibre, especially psyllium — 14 trials, 906 patients: about one in ten people you treat gets relief they wouldn't have otherwise. Bran (the insoluble kind) doesn't help and often makes pain and gas worse Moayyedi 2014.
Enteric-coated peppermint oil — global symptom relief at one in four, pain relief at one in seven. Side effects (mostly mild reflux) are more common than placebo Ingrosso 2022.
Low-dose amitriptyline — an old antidepressant in small doses (10–30 mg at night), used here as a gut-brain nerve dampener, not for mood. Twice as many people on it report a clinically meaningful response at six months as on placebo Ford 2023.
Rifaximin (for IBS-D) — a poorly-absorbed antibiotic; a two-week course produces lasting relief for about 41% versus 32% on placebo, and the response can be re-induced with a repeat course Pimentel 2011.
Gut-directed hypnotherapy and CBT — sustained improvement that persists after therapy ends, unlike most of the medications. Available as therapist-led courses and increasingly as app-based programs Black 2020.

What it costs you to leave it alone

Most people with IBS are not bedbound. They go to work. They have friends. They are managing — and the management is the cost.

The day looks like this. You check the menu before agreeing to lunch. You map every long meeting to where the nearest bathroom is. You eat less at dinner with your in-laws because you don't trust what's in the sauce. You decline the third coffee even though you want it, because the first two already started something. Your partner stops asking why you went quiet halfway through the movie; they know it's cramps. You explain "I have a sensitive stomach" so often it becomes a personality trait.

In the numbers: people with IBS score lower than peers on every domain of standard quality-of-life measures, with the worst dents in bodily pain, role limitations, and social functioning. Productivity at work drops by around 15 to 21 percent; in IBS with diarrhoea specifically, people miss about four more workdays a year than colleagues without it. Anxiety and depression coexist in roughly half of clinic populations — and the link runs both directions, with the gut amplifying the anxiety and the anxiety amplifying the gut Lacy 2021.

The "I'll just wait it out" plan also underestimates how long this lasts. Half of people who develop IBS after a bout of food poisoning still have it four years later; almost 40% still have it five years out Klem 2017. The clock on untreated IBS runs in years, not weeks.

The plan, in order

The American College of Gastroenterology and counterparts in Europe broadly agree on the order: a positive diagnosis with a short workup first, then diet and lifestyle, then a couple of cheap targeted add-ons, then prescription medications and behavioural therapy if symptoms persist Lacy 2021. Most people don't need every step. Climb the ladder until symptoms are tolerable, then stop.

Step 1: get the diagnosis nailed down

See a doctor with the symptom story written down — duration, pattern, what you eat, what makes it flare. The standard workup is short: a blood count, an inflammation marker (CRP or faecal calprotectin if diarrhoea is part of the picture), and a coeliac blood test if you have IBS-D or IBS-M Lacy 2021. No colonoscopy unless you have an alarm feature (see When it's not IBS, below) or you're over 45–50 and overdue for one anyway.

Step 2: do a structured low-FODMAP trial

FODMAPs are a group of short-chain carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) that draw water into the small bowel and ferment in the colon, producing the gas, distension and altered transit a hypersensitive gut feels as pain. The protocol developed at Monash University runs in three phases — not one.

Get a dietitian trained in the protocol if you possibly can. Self-directed FODMAP without one usually means people stay in phase 1 forever, miss hidden FODMAPs in stock and sauces, and end up on a needlessly restrictive long-term diet.

Step 3: add a cheap, targeted layer

Step 4: add a subtype-targeted medication, if you need one

If diet plus the above aren't enough, your clinician picks based on subtype.

For IBS-C: intestinal secretagogues — linaclotide (290 micrograms daily), plecanatide, or lubiprostone. They draw fluid into the bowel and ease both constipation and the abdominal pain that comes with it.
For IBS-D: loperamide on demand for predictable flares; rifaximin (550 mg three times daily for two weeks) as a one- or two-shot course that buys lasting relief for many Pimentel 2011. Eluxadoline and alosetron (women only, under a safety program) are reserved for severe cases.

Step 5: gut-brain neuromodulators and behavioural therapy

For pain that won't quit on diet and step-3 alone, low-dose amitriptyline (10–30 mg at night, titrated up) is the most evidence-supported pick. It's an old antidepressant being used here as a nerve-signal dampener at doses far below what's used for depression; the largest IBS trial of this approach showed clear benefit at six months and was well tolerated Ford 2023. SSRIs are second-line and tend to help more when anxiety or depression is also in the picture.

Brain-gut behavioural therapy — gut-directed hypnotherapy or cognitive behavioural therapy aimed at the gut-brain axis — works as well as the medications and the benefit lasts after the treatment ends Black 2020. Therapist-delivered courses run 6–10 sessions; app-based programs (Nerva, Mahana, Zemedy) deliver the same content for a fraction of the cost.

When it's not IBS

IBS is a positive diagnosis, but it has impostors. If any of the following are part of your picture, push for a colonoscopy and a broader workup before settling on IBS as the answer.

None of these are diagnostic of cancer or IBD by themselves — but none of them belong in an IBS story, and missing them is the failure mode that matters Lacy & Patel 2017.

On the treatment side, a few cautions worth knowing before a prescription gets written:

Low-dose amitriptyline — avoid with a recent heart attack, severe heart rhythm problems, or if you're on an MAO-inhibitor antidepressant; dose down in older adults.
Eluxadoline — not for anyone who's had their gallbladder out (pancreatitis risk) or with severe liver disease.
Low-FODMAP — don't try a restrictive elimination diet alone if you have a history of disordered eating, or if you're already losing weight without meaning to. The protocol assumes a stable nutritional baseline; it needs dietitian supervision in those situations.
Pregnancy and breastfeeding — the standard medication ladder shifts. Talk to your obstetrician before adding TCAs, rifaximin, or secretagogues; diet and behavioural therapy remain safe.

What most people get wrong

"It's all in your head." The gut-brain wiring is biological. Hypersensitive pain receptors, altered serotonin signalling, low-grade immune activation, and a shifted microbiome show up on biopsies and brain scans — none of that is psychogenic, even though stress modulates it Drossman 2016.
"Low-FODMAP is a lifelong diet." It's a three-phase tool — eliminate, reintroduce, personalise — meant to land on the least restrictive diet that keeps you comfortable. Staying in phase 1 forever does measurable damage to your microbiome and to your social life.
"IBS is just mild IBD." They're different diseases. IBS doesn't inflame, scar, bleed, or raise your cancer risk. A colonoscopy in IBS comes back normal — that's how you tell. The faecal calprotectin test is the cheap way to rule out IBD before scoping Lacy 2021.
"More fibre is always better." Insoluble bran often makes IBS worse — more gas, more pain. Soluble fibre (psyllium) is the form with the evidence Moayyedi 2014.
"My gut was permanently broken by that bout of food poisoning." Closer to true than not — post-infectious IBS is a real, named phenotype, with the highest risk after Campylobacter infection — but it's still IBS, and it responds to the same treatment ladder Klem 2017. It's not "damage", it's a calibration that hasn't reset.

Where this goes off the rails

Stuck in phase 1 of the diet. The most common failure. You eliminate FODMAPs, symptoms ease, the relief is real — and you never reintroduce. A year in, you're eating fifteen safe foods on rotation, your microbiome is narrower, and you can't go to a restaurant. Reintroduction is the work; do it, ideally with a dietitian.
Doing FODMAP self-directed. Hidden FODMAPs are everywhere — garlic powder in stock, fructans in commercial bread, polyols in sugar-free gum and mints. The Monash app or a dietitian catches what intuition misses. Without one, response rates drop and reintroduction rarely happens correctly.
Trying one thing and giving up. Moderate-to-severe IBS usually needs layers — diet plus a couple of cheap supplements plus, sometimes, a low-dose medication or therapy. Picking one and judging the whole protocol on it is how people end up convinced "nothing works."
Untreated anxiety or depression. Half of people with IBS in clinic also meet criteria for an anxiety or mood disorder, and the link runs both ways: untreated mental health worsens the gut, and a flaring gut worsens the mental health. Either side, treated alone, leaves the other side dragging.
Over-investigation. The other direction. A young person who meets Rome IV cleanly, with no red flags, doesn't need a second colonoscopy and a third abdominal CT. Repeated negative tests don't reassure — they reinforce the sense that something serious is being missed.

What it actually takes

Money. The cheap layer (Monash app, psyllium, peppermint oil capsules, a couple of dietitian sessions) lands in the low hundreds per year. Add prescription medications, brand-name secretagogues or rifaximin, or therapist-led behavioural therapy, and you're closer to one to two thousand a year before insurance. Generic amitriptyline at IBS doses is under fifty dollars a year. App-delivered behavioural therapy is tens of dollars a month.

Time. The first three months are work — reading every ingredient label, planning meals, tracking what you reintroduced and how it went. After that the diet shrinks back toward normal and the load is mostly habit. Behavioural therapy is 6–10 sessions over a couple of months; medications are taken-and-forgotten once the dose is set.

People. A dietitian trained in the Monash protocol is the single biggest practical lever. Ask. Many gastroenterologists keep a list; some IBS-focused primary-care clinics employ one in-house. Without that, the Monash FODMAP app (a one-time purchase under twenty dollars) is the next best thing.

Life around the protocol. Restaurants are the hardest part of phase 1 — most kitchens use onion and garlic in everything. It eases enormously in phase 3, when most foods come back. Travel and shift work both reliably flare IBS, by disrupting sleep and forcing unfamiliar meals; build in a few days of low-FODMAP defaults around big trips. Predictable mealtimes and reliable bathroom access at work are practical multipliers. So is how you eat, not just what: eating under stress — wolfing lunch at your desk between deadlines — feeds the gut-brain loop that flares IBS, so taking the actual lunch break, eaten slowly, is itself part of the treatment.

What changes when treatment works

Not everyone clears completely. About half to three-quarters of people who do the diet properly report meaningful global improvement; layering on a couple of medications and behavioural therapy lifts that further Halmos 2014 Lacy 2021. What "meaningful improvement" looks like, on a normal weekday:

First two to four weeks (elimination phase). Bloating drops first — your waistband fits the same way at 9 am and at 9 pm. Cramping eases. Stool form normalises toward the middle of the Bristol scale. Pain that used to land within an hour of meals stops landing.
Two to three months (reintroduction phase). You learn which foods are actually fine for you and which are not. The list of "off limits" usually shrinks to two or three FODMAP subgroups, not everything. Restaurants get easier. The mental tax of scanning every menu starts to lift.
Six months in. Bowel patterns are steady enough that you stop tracking them. The dread of upcoming meals — birthday dinner at the in-laws', work conference catering, a long-haul flight — quiets. People around you stop hearing "I'm not feeling great today" as often. Your partner stops asking if you're okay halfway through the movie.
A year in. Productivity claws back the four-or-so workdays a year you were losing to flare days Lacy 2021. Sleep stops getting interrupted by 3 am cramps. Mood and energy follow as the gut quiets — for the half of you who came in with anxiety on the side, that side eases too, especially if behavioural therapy was part of the stack Black 2020.

The benefits from the medication layer are real but typically wear off when the medication stops. The benefits from the dietary and behavioural layers — the personalised diet you've built, the gut-brain calibration that therapy reinforces — tend to persist. That's why the ladder is built the way it is: medications buy you a window; diet and behavioural work hold the gains.

Related conditions worth knowing

Several conditions either mimic IBS, overlap with it, or get missed when IBS is the working diagnosis:

Inflammatory bowel disease (Crohn disease, ulcerative colitis) — the most important not-IBS to rule out. Bleeding, weight loss, anaemia, or nocturnal symptoms move IBD ahead of IBS in the queue.
Coeliac disease — overlaps with IBS symptoms; a simple blood test (anti-tTG IgA) catches it.
Microscopic colitis — chronic watery diarrhoea in middle-aged and older women, especially. Looks normal on colonoscopy; only biopsy catches it.
Bile-acid diarrhoea — accounts for a quarter to a third of what's labelled IBS-D. Responds to a different class of medication (bile-acid sequestrants) than standard IBS-D care.
Lactose intolerance and fructose malabsorption — show up as IBS-shaped symptoms; a structured FODMAP reintroduction usually surfaces them.
Small intestinal bacterial overgrowth (SIBO) — a contested entity; some IBS-D responds to the same rifaximin courses used in IBS, which is part of why the SIBO–IBS boundary is blurry.
Functional dyspepsia — upper-gut version of the same gut-brain story; overlaps with IBS in about 40% of cases.
Colorectal cancer screening — new bowel-habit change after 45–50, or any red flag at any age, is the trigger to scope, regardless of how IBS-shaped the symptoms are.

Related in the handbook

Worsens / aggravates

— Stress is one of the biggest IBS triggers, and eating in a hurry feeds it. Slowing down and taking the actual lunch break is part of the treatment.

Helps

— If diet is the next step for your IBS, the low-FODMAP protocol is the structured way to find your triggers.
— When basic measures fail, a structured elimination diet is the most reliable dietary lever for IBS.
— Targeted probiotic strains are a mainstream IBS tool; match the strain to the symptom rather than buying any bottle.
— Gut-directed CBT and hypnotherapy are among the most effective IBS treatments — the gut-brain link cuts both ways.
— The fiber type matters in IBS: soluble usually soothes, insoluble can flare you — getting it right is half the battle.
— Soluble fiber like psyllium is a cheap first-line add-on — about one in ten get real relief.

Alternatives

— Before accepting diarrhea-predominant IBS, rule out the testable causes that mimic it — about one in three has one.

— Before you settle on IBS, rule out bile acid diarrhoea — it mimics IBS-D and has a specific fix.
— Bloating is one of the core IBS symptoms — and one of the first to ease on treatment.
— Your stool form on the Bristol scale is what sorts IBS into its constipation, diarrhea, or mixed subtype.
— IBS is the textbook gut-brain disorder — a miscalibrated conversation between bowel and brain.
— Before settling on an IBS label, rule out the red flags — blood, weight loss, night symptoms mean it isn't IBS.
— A lot of wheat-reactive IBS is the same picture as non-celiac gluten sensitivity, with FODMAPs as the shared culprit.
— Some IBS gets relabeled as SIBO — same symptoms, but the unreliable breath test muddies the picture.
— Constipation-predominant IBS and stubborn constipation blur together; if pain ties to your bowel habit, IBS may be the frame.
— IBS often travels with chronic pelvic pain in men — both are the gut-and-nerve sensitivity pattern, treated as a syndrome.
— If your gut symptoms ride your menstrual cycle and periods are brutal, ask about endometriosis - it's commonly mistaken for IBS.
— Some people labelled with IBS actually have histamine intolerance driving the symptoms.
— If you're tempted by a food-sensitivity panel for your gut, know it can't diagnose IBS — a proper workup and structured diet can.
— Spacing meals and skipping snacks can calm IBS-type symptoms by letting the gut reset between meals.

Substance and claimed effects

Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterised by recurrent abdominal pain related to defecation and a change in stool form or frequency, in the absence of structural disease Drossman & Hasler 2016. Rome IV operationalises the diagnosis (pain at least one day per week over the past three months, plus two of: pain related to defecation, change in frequency, change in form) and subtypes IBS by predominant stool form on the Bristol Stool Form Scale into IBS-C, IBS-D, IBS-M, and IBS-U Lacy & Patel 2017. The condition is positively diagnosed from symptoms and limited testing; it is not a diagnosis of exclusion Lacy et al. 2021. The entry covers Rome IV criteria, the four subtypes, the dietary management strategy anchored by the three-phase low-FODMAP protocol, and the consequences across stool patterns, abdominal pain, day-to-day function and work productivity, mood, sleep, energy, and quality of life. Pharmacological add-ons (soluble fibre, peppermint oil, tricyclic antidepressants, antispasmodics, rifaximin, secretagogues) are covered as the rest of the stepwise treatment ladder. IBD, microscopic colitis, coeliac disease and SIBO appear only as differentials and red-flag triggers, not as in-scope substances.

Evidence by addressing question

Mechanism

IBS is a disorder of gut-brain interaction: the gut and brain talk to each other through the vagus nerve, the enteric nervous system, immune signalling, microbial metabolites, and endocrine signals, and in IBS that conversation is miscalibrated Drossman & Hasler 2016. The clearest functional finding is visceral hypersensitivity — patients perceive normal gut distension and gas as painful at pressures healthy controls do not register, mediated by sensitised primary afferents in the splanchnic pathway and amplified central processing in the insula and anterior cingulate cortex Drossman & Hasler 2016. Stress activates the corticotropin-releasing factor system, which in turn increases mucosal permeability, ion secretion, and visceral hypersensitivity, providing a mechanism for the strong stress-flare relationship patients report Lacy et al. 2021. Low-grade mucosal inflammation, mast-cell activation, altered serotonin signalling (most 5-HT in the body is in enterochromaffin cells), and dysbiosis of the gut microbiome are convergent contributors. Post-infectious IBS (PI-IBS) is the cleanest experiment of nature: an acute bacterial or protozoal enteritis induces persistent immune activation, increased enteroendocrine cell counts, lymphocyte infiltration, and elevated mucosal permeability that can persist more than a year and produces IBS in roughly 10–14% of those infected Klem et al. 2017. The FODMAP mechanism is mechanical, not immune: fermentable short-chain carbohydrates (oligosaccharides, disaccharides, monosaccharides, polyols) draw water into the small bowel by osmosis and are fermented by colonic bacteria, producing gas and luminal distension. In a normo-sensitive gut this is unnoticed; in a hypersensitive gut it produces pain, bloating and altered transit.

Evidence

Symptom-based Rome IV criteria are durable: in secondary-care cohorts, >90% of patients meeting Rome IV continue to meet criteria on long-term follow-up, and organic disease only rarely emerges later Lacy & Patel 2017. Pooled global prevalence is 9.2% with Rome III and 3.8% with Rome IV across 53 and six countries respectively; the stricter Rome IV identifies fewer but more severely affected individuals Oka et al. 2020. For dietary management, a randomised crossover trial of 30 patients found a low-FODMAP diet produced significantly lower overall gastrointestinal symptom scores than a typical Australian diet (mean IBS-SSS reduction of approximately 22 points; pain, bloating and flatulence all reduced) Halmos et al. 2014. Subsequent meta-analyses of RCTs converge on a relative risk of approximately 1.5 for global symptom improvement versus control diets and a mean IBS-SSS reduction of about 45 points; the ACG 2021 guideline issued a conditional recommendation for a limited trial Lacy et al. 2021. Soluble fibre (especially psyllium) helps: 14 RCTs of 906 patients showed a relative risk of persistent symptoms of 0.86 (NNT 10), with the effect concentrated in soluble fibre and absent or harmful for insoluble bran Moayyedi et al. 2014. Peppermint oil is superior to placebo for global IBS symptoms (RR of not improving 0.65, NNT 4) and abdominal pain (NNT 7), with more frequent but mild adverse events Ingrosso et al. 2022. Low-dose tricyclic antidepressants have the largest evidence base among neuromodulators; the ATLANTIS trial randomised 463 primary-care adults to titrated amitriptyline 10–30 mg or placebo as second-line therapy and demonstrated significant superiority on the IBS-SSS at six months with good tolerability Ford et al. 2023. For IBS-D, two-week courses of rifaximin 550 mg three times daily produced adequate relief in 40.7% versus 31.7% on placebo across the TARGET 1 and TARGET 2 trials (P<0.001), with durability of effect over 10 weeks of post-treatment follow-up Pimentel et al. 2011. Brain-gut behavioural therapies (cognitive behavioural therapy and gut-directed hypnotherapy) are effective and persistent: a network meta-analysis of 41 RCTs in 4072 patients found self-administered or minimal-contact CBT and gut-directed hypnotherapy ranked highest, with effects maintained beyond the end of therapy Black et al. 2020.

Protocol

The ACG guideline frames a stepwise approach: positive diagnosis with limited testing (CBC, CRP/fecal calprotectin in IBS-D to exclude IBD, anti-tTG IgA to exclude coeliac in IBS-D and IBS-M), then lifestyle and dietary intervention, then symptom-targeted pharmacotherapy, then neuromodulators and brain-gut therapies for refractory cases Lacy et al. 2021. The low-FODMAP diet follows three phases developed at Monash University: (1) elimination of all high-FODMAP foods for 2–6 weeks, with response judged by symptom score; (2) systematic reintroduction of one FODMAP subgroup at a time across 6–8 weeks to identify personal triggers; (3) personalisation — a long-term liberalised diet restricting only the subgroups that reliably trigger symptoms. Phase 1 alone is not the diet; sustained phase-1 restriction risks nutritional deficiency and microbiome impoverishment. Subtype-targeted add-ons: for IBS-C, soluble fibre (psyllium 10–25 g/day, titrated to avoid gas), with intestinal secretagogues (linaclotide 290 µg daily, plecanatide, lubiprostone) where dietary measures fail; for IBS-D, loperamide (symptomatic), bile-acid sequestrants where bile-acid diarrhoea is suspected, and rifaximin 550 mg three times daily for two weeks (repeatable) Pimentel et al. 2011. Antispasmodics (dicyclomine, hyoscine, otilonium) and peppermint oil (180–225 mg enteric-coated, three times daily) help with cramping pain Ingrosso et al. 2022. Across subtypes, low-dose TCAs (amitriptyline 10–30 mg at night) titrated as a gut-brain neuromodulator are second-line for ongoing pain Ford et al. 2023. Brain-gut behavioural therapy (gut-directed hypnotherapy or CBT, increasingly via app-delivered protocols) is recommended for global symptoms across subtypes Black et al. 2020.

Contraindications

The diagnosis of IBS requires the absence of alarm features. Red flags that override a presumptive IBS diagnosis and trigger structural workup include unintentional weight loss ≥10% over six months, rectal bleeding or blood mixed with stool, iron-deficiency anaemia, nocturnal diarrhoea, new symptom onset after age 50, a family history of colorectal cancer or inflammatory bowel disease, and a palpable abdominal or rectal mass Lacy & Patel 2017. The ACG guideline recommends serologic testing for coeliac disease in IBS-D and IBS-M and faecal calprotectin in IBS-D to exclude IBD Lacy et al. 2021. Patients ≥45–50 years presenting with new bowel-habit change warrant colonoscopy per colorectal-cancer screening standards regardless of IBS-pattern symptoms. Pharmacological contraindications: TCAs are contraindicated with recent MI, severe arrhythmia, and concurrent MAO inhibitors, and require dose caution in the elderly; eluxadoline is contraindicated post-cholecystectomy (pancreatitis risk) and in severe hepatic impairment; alosetron (women with severe IBS-D only) carries an ischaemic colitis warning and is dispensed under a Risk Evaluation and Mitigation Strategy in the US. Low-FODMAP is not appropriate for patients with active eating disorders or significant unintentional weight loss without dietitian supervision.

Misconceptions

IBS is sometimes dismissed by clinicians and patients as "all in your head" — a framing the gut-brain interaction concept does not support: the disorder produces measurable changes in visceral perception, motility, mucosal immunity, microbiome composition, and central pain processing Drossman & Hasler 2016. A second misconception conflates IBS with IBD; the two are distinct (IBS has no inflammatory destruction, no cancer risk, normal colonoscopy and biopsies), though faecal calprotectin and limited testing are recommended to distinguish them Lacy et al. 2021. The third misconception is that low-FODMAP is a lifelong elimination diet; the evidence-based protocol is a three-phase tool — elimination, reintroduction, personalisation — and indefinite phase-1 restriction risks micronutrient deficiency and microbiome impoverishment. The fourth is that fibre uniformly helps; insoluble bran can worsen pain and bloating in IBS, while soluble fibre (psyllium) is the form supported by trials Moayyedi et al. 2014. The fifth, particularly for IBS-D, is the misattribution of post-infectious symptoms to lasting "food poisoning damage" — they are the well-documented PI-IBS phenotype, and onset within months of a documented enteritis is a useful diagnostic anchor Klem et al. 2017.

Failure modes

The most common dietary failure is permanent phase-1 of the low-FODMAP diet without reintroduction — symptom control is achieved but the long-term diet is more restrictive than necessary, harder socially, and may impoverish the microbiome. Self-directed low-FODMAP without a dietitian or app fails by underestimating hidden FODMAP sources (onion in stock, fructans in wheat, polyols in sugar-free gum) and by collapsing the protocol's structure. The second failure mode is skipping the differential workup: anaemic IBS-D is IBD until proven otherwise; new-onset symptoms over 50 require colonoscopy; nocturnal diarrhoea is not IBS. The third is single-modality treatment: most patients with moderate-to-severe IBS need dietary plus pharmacological plus behavioural intervention layered, not picked from Lacy et al. 2021. The fourth is undertreated mental health comorbidity (anxiety and depression are present in roughly half of IBS clinic populations); the bidirectionality means untreated anxiety amplifies visceral hypersensitivity and limits dietary response. The fifth is over-investigation — repeat colonoscopies and serial abdominal CT in a young patient meeting Rome IV with no alarm features deliver no diagnostic yield and reinforce illness identity.

Practicalities

Low-FODMAP requires structured support; Monash University's app (one-time purchase ~USD 10) and a referral to a registered dietitian familiar with the protocol are the standard. Without dietitian guidance, response rates fall and reintroduction is rarely completed correctly. Cost: peppermint oil and psyllium are over-the-counter, low cost (under USD 100/year). Linaclotide, plecanatide, lubiprostone, eluxadoline and rifaximin are prescription-only and brand-name in most markets — USD several hundred to several thousand per year before insurance. Low-dose generic amitriptyline is inexpensive (under USD 50/year). Brain-gut behavioural therapy is increasingly available via app-delivered programs (Nerva, Mahana, Zemedy) for tens of dollars per month; therapist-delivered gut-directed hypnotherapy or CBT runs USD 100–250 per session over 6–10 sessions. Workplace bathroom access and predictable mealtimes are practical determinants of management feasibility, especially for IBS-D. Travel and shift work consistently worsen symptoms via disrupted circadian rhythms and unfamiliar food exposures.

Stakes

Untreated IBS is not a benign nuisance. Patients with IBS report SF-36 scores lower than controls across every domain, with the largest decrements in bodily pain, role limitations and social functioning. Work productivity loss is substantial: employees with IBS report 15–21% reduction in productivity, with IBS-D specifically associated with 5.1% absenteeism (vs 2.9% in controls) and an additional ~4 missed workdays per year. Roughly half of IBS cases meeting Rome IV in primary care also meet criteria for anxiety or depression, with bidirectional reinforcement. Healthcare utilisation is high: repeat consultations, endoscopies, and unfocused supplement trials accumulate cost. Post-infectious IBS persists at 52% at 1–4 years follow-up and 39.5% at 5 years Klem et al. 2017 — the "I'll just wait it out" mental model substantially underestimates duration.

Payoff

Response rates for the structured stepwise approach are meaningful. Low-FODMAP delivers global symptom improvement in approximately 50–75% of patients, with the largest gains in bloating and abdominal pain by week 2–4 of elimination Halmos et al. 2014. Peppermint oil yields global symptom relief at NNT 4 and pain relief at NNT 7 within weeks Ingrosso et al. 2022. Amitriptyline 10–30 mg titrated over 6 months produces durable symptom-severity reductions in primary-care IBS, with patients twice as likely to report a clinically meaningful response as on placebo Ford et al. 2023. Gut-directed hypnotherapy and CBT (including app-delivered programs) produce sustained reductions in symptom severity that persist after therapy ends, distinguishing them from pharmacotherapy alone Black et al. 2020. Quality of life gains follow symptom gains — IBS-QoL improves on low-FODMAP, on rifaximin in IBS-D, and on linaclotide in IBS-C in their respective RCTs.

Out-of-scope (forward links)

Differentials and adjacent topics that warrant separate entries when written: inflammatory bowel disease (Crohn disease, ulcerative colitis); coeliac disease; small intestinal bacterial overgrowth (SIBO); bile-acid diarrhoea; lactose and fructose malabsorption; functional dyspepsia (overlaps IBS in ~40%); microscopic colitis (a frequent missed diagnosis in older women with IBS-D-like symptoms); colorectal cancer screening (the alarm-feature trigger). The gut microbiome and dysbiosis themes overlap heavily but are mechanistic context, not separate substances.

Credibility range

Optimist case

Rome IV is a robust, replicated, internationally validated symptom-based diagnosis whose stability on follow-up rivals biomarker-based diagnoses Lacy & Patel 2017. The mechanism — gut-brain interaction with visceral hypersensitivity, dysbiosis, immune activation, and disturbed motility — has converging evidence from imaging, mucosal biopsies, microbiome sequencing, and post-infectious natural experiments Drossman & Hasler 2016. Low-FODMAP is supported by multiple positive RCTs and meta-analyses with effect sizes that exceed almost any other dietary intervention in gastroenterology Halmos et al. 2014 Lacy et al. 2021. Multiple drug classes (peppermint oil, soluble fibre, TCAs, rifaximin, secretagogues) have RCT and meta-analytic support with NNTs in single digits Ingrosso et al. 2022 Moayyedi et al. 2014 Ford et al. 2023 Pimentel et al. 2011. Brain-gut behavioural therapy delivers persistent post-treatment benefit, which most pharmacotherapy does not Black et al. 2020. The combination — positive diagnosis, stepwise dietary then pharmacological then behavioural escalation — produces meaningful symptom and quality-of-life improvement in the majority of patients who engage with the protocol.

Skeptic case

Rome IV identifies a heterogeneous population — IBS-C, IBS-D, IBS-M, post-infectious IBS, anxiety-predominant IBS, and dietary-trigger-predominant IBS may share little pathophysiology beyond the syndromic definition. Many trials are short (8–12 weeks), unblinded for dietary interventions (the Halmos crossover had ~83% diet-arm recognition), and dependent on subjective endpoints, inflating apparent effect sizes. Low-FODMAP elimination compresses the microbiome (reduced bifidobacteria) and may have long-term consequences that short trials cannot capture; reintroduction phase compliance in real-world cohorts is far below the protocol ideal. Peppermint oil's pooled evidence is rated low- to very-low-certainty by Cochrane methodology, with substantial heterogeneity across trials Ingrosso et al. 2022. Rifaximin's effect size is modest (NNT ~11) and the underlying small intestinal bacterial overgrowth model remains contested Pimentel et al. 2011. Commercial actors (low-FODMAP food companies, rifaximin manufacturer, app-based behavioural therapy startups) have skin in framing IBS as treatable through their product. Diagnostic-criteria drift (Rome III to Rome IV more than halved point prevalence) suggests the syndrome boundary is partly definitional Oka et al. 2020.

Author's call

IBS is real, common, debilitating, and treatable, and the spec's bar — clearer, more accurate, more actionable mental model — sits squarely on the optimist side of the evidence. The diagnosis is well-defined (Rome IV); the symptom burden and quality-of-life cost are substantial; multiple interventions across diet, pharmacology and brain-gut therapy have RCT-level evidence with clinically meaningful NNTs. The article should anchor low-FODMAP three-phase as the highest-yield first-line dietary move, name soluble fibre and peppermint oil as low-cost first additions, and escalate to neuromodulators and behavioural therapy without hedging that they are last-resort. Honest framing of the constraints — get a dietitian for FODMAP, do the workup to exclude IBD/coeliac, treat coexisting anxiety — earns the optimist position its credibility. Evidence score: 4 (multiple converging RCTs and meta-analyses but condition heterogeneity prevents 5). Controversy score: 2 (mechanism specifics are debated but treatment ladder is broadly agreed).

Stakeholder + incentive map

Gastroenterology professional bodies (ACG, AGA, BSG, NICE) — issue and update IBS guidelines; converging on the stepwise model with low-FODMAP and behavioural therapy Lacy et al. 2021.
Pharmaceutical incentives — manufacturers of rifaximin (Salix), linaclotide (Allergan/AbbVie), eluxadoline (Allergan), plecanatide (Synergy/Salix), tenapanor (Ardelyx) and lubiprostone (Sucampo/Mallinckrodt) actively market subtype-targeted agents. The TARGET 3 trial design (repeat-treatment efficacy) was sponsor-funded Pimentel et al. 2011.
Monash University FODMAP program — academic origin, commercial app and certification, central position in dietary guidance. Influence is largely positive but creates incentive to position low-FODMAP as universal first-line.
App-delivered behavioural therapy companies — Nerva (hypnotherapy), Mahana (CBT), Zemedy (CBT) compete to lower the cost and access barrier; benefit from RCT-level data.
Patient advocacy and online community — Reddit /r/ibs, IFFGD, About IBS provide peer support; bias toward over-reporting dramatic failures and dramatic responses, under-reporting average results.
Skeptic / counter-incentive — primary-care clinicians under time pressure may give a diagnosis without a structured plan; this reinforces patient perception that IBS is a "wastebasket" diagnosis.

Population variability

Female predominance is consistent across studies, roughly 1.5–2:1 female:male in clinical populations and modestly attenuated in community samples. Onset is typically before 50; new onset after 50 is an alarm feature. Post-infectious IBS skews female and toward those with prolonged or severe acute enteritis; Campylobacter has the highest risk among bacterial pathogens (~21% develop PI-IBS) Klem et al. 2017. Comorbid anxiety and depression are present in roughly half of clinic cohorts and modulate symptom severity and treatment response — patients with higher baseline distress respond better to neuromodulators and behavioural therapy Ford et al. 2023. Subtype distribution varies geographically: IBS-D more common in Western cohorts, IBS-C more common in some Asian cohorts. Low-FODMAP response is most pronounced in patients with prominent gas/bloating and meal-related symptoms; less impressive in opioid-related constipation or in IBS where psychological factors dominate. TCA response is stronger in IBS-D than IBS-C (anticholinergic mechanism aligns with the diarrhoea phenotype) Ford et al. 2023. Older adults (≥50) require pre-diagnosis colonoscopy and dose caution for TCAs and antispasmodics.

Knowledge gaps

Long-term safety of indefinite low-FODMAP restriction is not well characterised — most trials run 4–12 weeks and few follow microbiome composition or micronutrient status past a year. Biomarker-based subtype prediction (who responds to which therapy) remains an unmet need; current matching is largely subtype-symptom based and trial-and-error. Real-world adherence to the three-phase FODMAP protocol — particularly reintroduction and personalisation — is poorly studied; clinical impression suggests most patients stall in phase 1. The relative effect of microbiome-targeted interventions (specific probiotics, faecal microbiota transplantation) remains uncertain; current strain-by-strain trial evidence is mixed, and meta-analyses are difficult to interpret. The relationship between IBS, bile-acid diarrhoea (~25–30% of IBS-D), and SIBO is contested. Long-term outcomes of brain-gut behavioural therapy at 5+ years post-treatment are sparse. Mechanistic understanding of why anxiety modulates visceral hypersensitivity (and whether targeting one reliably treats the other) is incomplete.

Brief vs entry. The brief named Rome IV, subtypes, low-FODMAP, stool patterns, abdominal pain, and quality of life. All covered. The article also covers the rest of the ACG stepwise ladder (soluble fibre, peppermint oil, TCAs, rifaximin, secretagogues, brain-gut behavioural therapy) because the consequences-of-the-substance rule means you can't honestly cover "effects on quality of life" without covering the management that produces those effects. No silent narrowing.

Hard scoping calls.

Action: respond, not know or decide. The reader is almost always already symptomatic; the entry is a protocol they execute when symptoms are present. know understated it; decide implies a single tradeoff with clinician input, when most of the protocol is self-directed.
Cadence: course, not daily or as-needed. The most distinctive intervention — the three-phase low-FODMAP protocol — is bounded with a defined endpoint (personalisation). Day-to-day management afterwards is mostly habit. course captures the structured-with-endpoint nature; daily would mis-cue an indefinite restriction the protocol explicitly warns against.
Longevity scored 0, not 1. Honest call: IBS does not raise all-cause mortality in cohort data; treating it doesn't extend life. Inflating to 1 to avoid an awkward zero would be exactly the bias the scoring rules warn against.
Sleep scored 2, not higher. IBS disrupts sleep through pain, anxiety, and bedtime rumination, and treatment improves it — but true nocturnal diarrhoea is a red flag, so the sleep dimension is bounded by what the diagnosis itself permits.
No audience scoping. Female-skewed (1.5–2:1 in clinic) but not female-exclusive; the entry applies to adults across all genders and age bands <50, and the over-50 caution lives in the contraindications section rather than as a meta-level age scope.

Rating difficulties.

Evidence scored 4 rather than 5. Each individual lever (Rome IV criteria, low-FODMAP, fibre, peppermint, TCAs, rifaximin, behavioural therapy) has RCT and meta-analytic support, but the syndrome itself is heterogeneous and treatment-response prediction by subtype is still imprecise. A 5 ("multiple large RCTs, Cochrane-level, guideline-backed") fits each lever in isolation but not the IBS-as-managed-condition as a whole.
Controversy scored 2, not 3. Mechanism details (SIBO contribution, role of microbiome-targeted therapies, long-term safety of restrictive elimination) are genuinely contested, but the stepwise treatment ladder is broadly agreed across ACG, AGA, BSG and NICE — that's not "active debate among reasonable experts" at the level a 3 would imply.

Separate-entry candidates surfaced during the write.

Inflammatory bowel disease (Crohn, ulcerative colitis) — the most important IBS-mimic.
Coeliac disease — IBS-D and IBS-M overlap.
Microscopic colitis — chronic watery diarrhoea in older women, normal colonoscopy.
Bile-acid diarrhoea — 25–30% of "IBS-D" is actually this; bile-acid sequestrants are the right treatment.
SIBO — contested entity, overlap with IBS, deserves its own entry.
Functional dyspepsia — sibling disorder of gut-brain interaction, 40% IBS overlap.
Low-FODMAP diet — could be split out as its own entry if the catalogue grows toward diet-specific protocols.
Gut-directed hypnotherapy (and app-based brain-gut therapy) — own entry candidate.
Psyllium — own entry candidate; cited here and likely in constipation, cholesterol, and weight entries.
Faecal calprotectin — diagnostic test entry candidate.

Future links to wire in when those entries exist. The out-of-scope section is currently prose pointers without cross-links; once IBD, coeliac, microscopic colitis, bile-acid diarrhoea, and SIBO entries land, this entry's related meta field should be updated.

Excluded deliberately. Specific probiotic strain recommendations — current trial evidence is mixed enough that naming a strain would be over-confident. Faecal microbiota transplantation for IBS — investigational, mixed trials. Cannabis-derived therapies — preliminary, no guideline support. Each could earn its own entry as evidence matures.